{"result": {"id": "54c953a1-26f1-4e93-8dbd-9d229c303d49", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>中国医疗保健国际交流促进会高血压分会共识专家组<|>ORGANIZATION<|>A Chinese expert group focused on hypertension management and consensus development>)  \n##\n(\"entity\"<|>高尿酸血症相关疾病诊疗多学科共识专家组<|>ORGANIZATION<|>A multidisciplinary expert group for the diagnosis and treatment of hyperuricemia-related diseases in China>)  \n##\n(\"entity\"<|>AMERICAN COLLEGE OF RHEUMATOLOGY<|>ORGANIZATION<|>An organization providing guidelines for the management of gout>)  \n##\n(\"entity\"<|>CSPPT<|>ORGANIZATION<|>A randomized clinical trial group studying folic acid therapy for stroke prevention in hypertensive patients>)  \n##\n(\"entity\"<|>LIFE<|>ORGANIZATION<|>A study group reviewing cardiovascular morbidity and mortality in hypertensive patients>)  \n##\n(\"entity\"<|>COCHRANE DATABASE SYSTEMATIC REVIEW<|>ORGANIZATION<|>A database providing systematic reviews on medical interventions>)  \n##\n(\"entity\"<|>KJEKSHUS JK<|>PERSON<|>Researcher studying beta-blocker efficacy in myocardial infarction>)  \n##\n(\"entity\"<|>CUCHERAT M<|>PERSON<|>Researcher analyzing heart rate reduction benefits post-myocardial infarction>)  \n##\n(\"entity\"<|>FITZGERALD JD<|>PERSON<|>Contributor to rheumatology guidelines for gout management>)  \n##\n(\"entity\"<|>BORGHI C<|>PERSON<|>Expert in hyperuricemia and cardiovascular risk>)  \n##\n(\"entity\"<|>OHTA Y<|>PERSON<|>Researcher on uric acid-lowering treatments for hypertensive patients>)  \n##\n(\"entity\"<|>HUO Y<|>PERSON<|>Lead researcher in the CSPPT clinical trial on folic acid therapy>)  \n##\n(\"entity\"<|>BANG CN<|>PERSON<|>Researcher on cardiovascular morbidity in hypertensive patients>)  \n##\n(\"entity\"<|>PASCUAL JM<|>PERSON<|>Researcher on microalbuminuria in hypertension>)  \n##\n(\"entity\"<|>CHOWDHURY EK<|>PERSON<|>Researcher on renal function and mortality in elderly hypertensive patients>)  \n##\n(\"entity\"<|>WILLEIT P<|>PERSON<|>Researcher on carotid intima-media thickness as a cardiovascular risk marker>)  \n##\n(\"entity\"<|>WANG JG<|>PERSON<|>Researcher on carotid intima-media thickness and antihypertensive treatment>)  \n##\n(\"entity\"<|>SHETTY S<|>PERSON<|>Researcher on calcium channel blockers and peripheral arterial disease>)  \n##\n(\"entity\"<|>NATALE P<|>PERSON<|>Researcher on ACE inhibitors and angiotensin receptor blockers for diabetic kidney disease>)  \n##\n(\"entity\"<|>CHEN JS<|>PERSON<|>Researcher on antihypertensive drugs and left ventricular hypertrophy>)  \n##\n(\"entity\"<|>TAKAMI T<|>PERSON<|>Researcher on cardiovascular remodeling and antihypertensive drugs>)  \n##\n(\"relationship\"<|>中国医疗保健国际交流促进会高血压分会共识专家组<|>高尿酸血症相关疾病诊疗多学科共识专家组<|>Both are Chinese expert groups focused on hypertension and hyperuricemia management<|>4>)  \n##\n(\"relationship\"<|>FITZGERALD JD<|>AMERICAN COLLEGE OF RHEUMATOLOGY<|>FitzGerald contributed to the rheumatology guidelines for gout management<|>7>)  \n##\n(\"relationship\"<|>HUO Y<|>CSPPT<|>Huo Y led the CSPPT clinical trial on folic acid therapy<|>8>)  \n##\n(\"relationship\"<|>BANG CN<|>LIFE<|>Bang CN contributed to the LIFE study on cardiovascular morbidity<|>7>)  \n##\n(\"relationship\"<|>NATALE P<|>COCHRANE DATABASE SYSTEMATIC REVIEW<|>Natale P contributed to a systematic review on diabetic kidney disease<|>6>)  \n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558941, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 930, "prompt_tokens": 2861, "total_tokens": 3791, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 1069}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: :  348.\n[380]  KjekshusJK.  Importanceofheartrateindeterminingbeta-bloc- kerefficacy in acute and long-term acute myocardial infarction intervention trials[J]. Am JCardiol,1986,57(12) :43F-49F.\n[381]  CucheratM.  Quantitativerelationshipbetweenrestingheartrate reduction and magnitude of clinicalbenefits in post-myocardial infarction: ameta-regressionofrandomizedclinicaltrials[J]. Eur HeartJ,2007,28(24) :3012-3019.\n[382]  中国医疗保健国际交流促进会高血压分会共识专家组.  高血压 伴无症状高尿酸血症管理中国专家共识[J]. 中华高血压杂志 , 2022,30(11) :1014-1019.\n[383]  FitzGeraldJD, DalbethN, MikulsT, etal. 2020AmericanCol- legeofRheumatologyguidelineforthemanagementofgout[J].   ArthritisRheumatol,2020,72(6) :879-895.\n\n\n[384]  高尿酸血症相关疾病诊疗多学科共识专家组.  中国高尿酸血症 相关疾病诊疗多学科专家共识[J]. 中华内科杂志 ,2017, 56(3) : 235-248.\n[385]  BorghiC, TykarskiA, WideckaK, etal.  Expertconsensusfor the diagnosis and treatment of patient with hyperuricemia and high cardiovascularrisk[J]. CardiolJ,2018,25(5) :545-563.\n[386]  OhtaY, IshizukaA, Arima H, etal. Effectiveuricacid-lower- ing treatmentforhypertensive patients with hyperuricemia[J].   HypertensRes,2017,40(3) :259-263.\n[387]  Huo Y, LiJ, Qin X, etal. Efficacyoffolicacidtherapyin pri- mary prevention of stroke among adults with hypertension in China: theCSPPT randomizedclinicaltrial[J]. JAMA,2015,313\n(13) :1325-1335.\n[388]  BangCN, DevereuxRB, OkinPM.  Regressionofelectrocardio- graphicleftventricular hypertrophy or strain is associated with lowerincidenceofcardiovascularmorbidity and mortalityin hy- pertensive patients independent of blood pressure reduction-a LIFE review[J]. J Electrocardiol,2014,47(5) :630-635.\n[389]  PascualJM, RodillaE, CostaJA, etal. Prognosticvalueofmi- croalbuminuria during antihypertensive treatment in essential hypertension[J]. Hypertension,2014,64(6) :1228-1234.\n[390]  ChowdhuryEK, Langham RG, AdemiZ, etal. Rateofchange in renalfunctionandmortalityinelderlytreatedhypertensivepa- tients[J]. ClinJAm SocNephrol,2015,10(7) :1154-1161.\n[391]  WilleitP, TschidererL, AllaraE, etal.  Carotid intima-media thickness progression as surrogate marker for cardiovascular risk: meta-analysis of 119 clinical trials involving 100 667 pa- tients[J]. Circulation,2020,142(7) :621-642.\n[392]  WangJG, StaessenJA, LiY, etal. Carotidintima-mediathick- nessandantihypertensivetreatment: ameta-analysisofrandom- ized controlledtrials[J]. Stroke,2006,37(7) :1933-1940.\n[393]  ShettyS, MalikAH, FeringaH, etal. Meta-analysisevaluating calcium channelblockers and the risk of peripheral arterialdis- easeinpatientswith hypertension[J]. Am J Cardiol, 2020, 125\n(6) :907-915.\n[394]  NataleP, PalmerSC, NavaneethanSD, etal.  Angiotensin-con- verting-enzymeinhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease[J]. Co- chraneDatabaseSystRev,2024,4(4) :CD006257.\n[395]  ChenJS, PeiY, LiCE, etal. Comparative efficacy ofdifferent typesofantihypertensive drugs in reversing left ventricular hy- pertrophy as determined with echocardiographyin hypertensive patients: anetworkmeta-analysisofrandomizedcontrolledtrials [J]. J Clin Hypertens(Greenwich) ,2020,22(12) :2175-2183.\n[396]  TakamiT, HoshideS, KarioK.  Differentialimpactofantihy- pertensivedrugson cardiovascularremodeling: a review offind- ings andperspectivesforHFpEFprevention\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_42794dd04a30830416a3f8602f32741377f1503168c4ba1f5539d50742cb1a48_v2"}